BRAF and neoplasm: Consistently, data from a metastatic cohort, presented here, confirm that BRAF mutations in biopsies from the patients’ primary tumor display MSI high in 37.8% of cases while biopsies from metastatic sites in similar BRAF mutated cancer patients from the same cohort showed MSI high in 11.5% of cases.